Medtronic reported a strong start to fiscal 2027 as first-quarter revenue increased at a double-digit rate across each of its major business segments, earnings improved significantly and management raised its full-year revenue and earnings outlook.
First-quarter revenue reached $9.76 billion, increasing 13.7% both as reported and organically.
The result was approximately 200 basis points above the midpoint of Medtronic’s previous guidance, reflecting stronger-than-expected performance across its diversified medical technology portfolio.
GAAP diluted earnings per share reached $1.14, while non-GAAP diluted EPS was $1.45.
GAAP operating profit increased to $1.76 billion from $1.45 billion in the prior-year period, representing growth of approximately 21%.
Net income attributable to Medtronic increased even faster, rising to $1.47 billion from $1.04 billion a year earlier.
The improvement in earnings alongside double-digit organic revenue growth reflects a quarter in which Medtronic benefited from both increased procedure volumes and stronger contributions from newer products across several of its largest businesses.
Growth was broad-based across the company.
Cardiovascular delivered the strongest performance among Medtronic’s major operating segments, with revenue increasing 18.9% organically.
Neuroscience revenue increased 9.3% organically, while Medical Surgical grew 10.2% and Diabetes increased 14.9%.
The fact that all four major businesses generated high-single-digit or double-digit organic growth was an important component of the quarter because it reduced reliance on any single product category or therapeutic market.
Within Cardiovascular, several businesses produced especially strong results.
Cardiac Rhythm Management revenue increased 15%, reflecting continued demand across technologies used to diagnose and treat heart rhythm disorders.
Cardiac Ablation Solutions delivered one of the most significant growth rates in the portfolio, with revenue increasing 88%.
That performance highlights the growing importance of cardiac ablation within Medtronic’s cardiovascular strategy as the company expands technologies for treating cardiac arrhythmias.
The rapid growth of Cardiac Ablation Solutions also illustrates management’s emphasis on newer growth platforms that can supplement established businesses and increase the overall growth rate of the portfolio.
Medtronic additionally highlighted strong performance within Cranial and Spinal Technologies and Acute Care & Monitoring.
These businesses give the company exposure to neurological and spinal procedures as well as technologies used to monitor and manage patients across hospital and acute-care environments.
The breadth of the quarter’s performance was particularly important to management’s increased confidence in the remainder of fiscal 2027.
Rather than relying on one unusually strong business, Medtronic generated growth across Cardiovascular, Neuroscience, Medical Surgical and Diabetes.
That diversification can provide greater stability because procedure trends and product cycles can vary substantially between individual medical technology categories.
The fiscal calendar provided an additional benefit during the quarter.
Medtronic’s first quarter contained an extra fiscal week, which the company estimated contributed approximately $570 million of organic revenue.
That benefit should be considered when evaluating the 13.7% year-over-year revenue increase because it provided a meaningful contribution to reported quarterly growth.
Even with the calendar effect, however, management said the quarter came in roughly 200 basis points above the midpoint of its previous organic growth expectations.
That stronger performance helped support an increase in the company’s full-year outlook.
Medtronic raised fiscal 2027 organic revenue growth guidance by 50 basis points to a range of 7.25% to 7.75%.
At the midpoint, the new guidance implies approximately 7.5% organic revenue growth for the year.
The company also increased its non-GAAP diluted EPS outlook to $5.94 to $6.00.
At the midpoint, that represents approximately $5.97 per share.
The higher guidance reflects management’s confidence that demand and execution across Medtronic’s portfolio will remain strong beyond the unusually favorable first-quarter calendar.
Medtronic’s expanding innovation pipeline is another part of that outlook.
The company operates across cardiovascular devices, neuroscience technologies, surgical systems, diabetes products and other medical technology categories, giving it multiple opportunities to introduce new devices and expand existing platforms.
New product adoption can be particularly important in medical technology because recently launched devices can carry faster growth rates than mature products and can help manufacturers increase market share.
Management specifically pointed to increasing contributions from newer growth platforms as a reason for confidence in the company’s trajectory.
The results suggest that those products are becoming meaningful enough to influence growth across several businesses.
Cardiac Ablation Solutions provides one of the clearest examples, with its 88% revenue increase substantially exceeding the overall company’s growth rate.
Strong growth in Cardiac Rhythm Management, Diabetes and other product areas further broadened the contribution.
Diabetes revenue increased 14.9% organically, continuing to make the segment an important source of growth.
Diabetes technology has increasingly shifted toward more automated and connected systems designed to improve glucose management while reducing the amount of manual intervention required from patients.
Continued double-digit growth in the segment adds another growth engine alongside Medtronic’s much larger Cardiovascular operation.
Medical Surgical also posted 10.2% organic growth, showing continued demand across products used in surgical procedures and hospital settings.
Neuroscience’s 9.3% organic increase provided another meaningful contribution from a business spanning neurological and spinal technologies.
Together, these results demonstrate the advantage of Medtronic’s diversified operating structure.
A company with exposure to multiple medical specialties can participate in broader healthcare procedure growth while reducing dependence on any one device category.
The earnings results also show that the stronger revenue environment translated into higher profitability.
GAAP operating profit increased by approximately $310 million year-over-year to $1.76 billion.
Net income attributable to Medtronic increased by approximately $430 million to $1.47 billion, representing growth of more than 40%.
That pace of net income expansion substantially exceeded revenue growth during the quarter.
GAAP diluted EPS of $1.14 and non-GAAP diluted EPS of $1.45 provide two measures of the earnings generated from the higher sales base.
The increase in operating profit gives Medtronic additional resources to reinvest in research and development, commercial expansion and new product launches.
Innovation spending is particularly important in medical devices because companies must continuously develop new technologies while navigating clinical testing, regulatory approvals and physician adoption.
Medtronic’s size allows it to fund those initiatives across several therapeutic categories simultaneously.
The first-quarter performance suggests that some of those investments are translating into faster-growing product platforms.
The company’s higher guidance also raises expectations for the remainder of fiscal 2027.
While the extra fiscal week provided approximately $570 million of first-quarter organic revenue, management’s decision to increase full-year organic growth expectations indicates that the improved outlook extends beyond that calendar benefit.
Medtronic now expects the underlying business to grow between 7.25% and 7.75% organically for the full year.
Achieving that range would require continued strength across its largest businesses as well as contributions from recently introduced technologies.
Cardiovascular will remain especially important given its 18.9% organic growth and the scale of the segment.
The continued expansion of Cardiac Ablation Solutions could provide an additional catalyst if adoption remains strong.
Diabetes, Cranial and Spinal Technologies and Acute Care & Monitoring also provide opportunities for continued growth.
Overall, Medtronic’s fiscal first quarter combined stronger-than-expected revenue with broad-based segment growth and significantly higher profitability.
Revenue reached $9.76 billion, GAAP operating profit increased to $1.76 billion, and net income attributable to Medtronic rose to $1.47 billion.
Cardiovascular organic revenue increased 18.9%, including 88% growth in Cardiac Ablation Solutions, while Neuroscience, Medical Surgical and Diabetes all posted strong organic increases.
Although approximately $570 million of organic revenue came from the extra fiscal week, the company’s performance still exceeded its previous guidance and led management to raise expectations for the remainder of fiscal 2027.
With full-year organic revenue growth now projected at 7.25% to 7.75% and non-GAAP diluted EPS expected at $5.94 to $6.00, Medtronic enters the rest of the fiscal year with stronger momentum and increasing contributions from newer growth platforms across its portfolio.
KEY QUOTES:
“We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms. Our execution, alongside our innovation engine, positions us to serve more patients and deliver durable growth. The strength of our portfolio and pipeline gives us confidence in the opportunities ahead.”
Geoff Martha, Chairman and Chief Executive Officer of Medtronic
